Branded Generics Market Size

Branded generics Market Size

Branded Generics Market size accounted for USD 238.4 billion in 2022 and is estimated to grow at 6.1% to reach USD 447.8 billion by 2032. The increasing number of patent expiry is set to provide a substantial boost to the market.

To get key market trends

  Download Free Sample

For instance, some of the popular medications, including Humira from AbbVie, Januvia & Janumet from Merck, and Victoza from Novo Nordisk, among others, is expected to observe patent expiry in 2023. Therefore, such scenario creates a favourable landscape for generic drug manufacturers to step in. These branded generics offer equivalent therapeutic benefits as the original branded drugs at a lower cost. This cost-effectiveness serves as a major factor driving the demand for these alternatives.
 

Branded generics, also known as "branded off-patent generics" or "value-added generics," refer to pharmaceutical products that are off-patent but are marketed under a brand name by a company other than the one that originally developed by the drug. These products are essentially generic versions of previously patented drugs that have lost their exclusivity, allowing other manufacturers to produce and sell equivalent versions of the medication.